Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33722419.
- Also identified by DOI 10.1016/j.eururo.2021.02.032.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Men with metastatic germ cell tumors undergoing chemotherapy are at high risk of venous thromboembolic events and low risk of bleeding. A central venous-access device should be avoided whenever possible. Thromboprophylaxis may be prescribed after balancing the risks and benefits for each individual patient.
Medical subject headings
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Second Primary
- Testicular Neoplasms
- Urology
- Venous Thromboembolism